Long-term follow-up demonstrates durable clinical benefits of exagamglogene autotemcel for sickle cell disease with recurrent vaso-occlusive crises: Final results of climb SCD-121
Stephan A. Grupp(Children's Hospital of Philadelphia), Haydar Frangoul(Children’s Hospital at TriStar Centennial), Mariane de Montalembert(Hôpital Necker-Enfants Malades), Marina Cavazzana(Université Rennes 2), Paul Telfer(Queen Mary University of London), Franco Locatelli(Bambino Gesù Children's Hospital), Lyndsay Molinari, Damiano Rondelli(University of Illinois Chicago), Monica Bhatia(Columbia University Irving Medical Center), Mark C. Walters(UCSF Benioff Children's Hospital), Kevin H.M. Kuo(University Health Network), Martin H. Steinberg(Boston Medical Center), Robert I. Liem(Lurie Children's Hospital), Stephan Lobitz(Gemeinschaftsklinikum Mittelrhein), Ami J. Shah(University of California, Los Angeles), Akshay Sharma(St. Jude Children's Research Hospital), Michael J. Eckrich(Levine Children's Hospital), Tina Liu, Suzan Imren(Fred Hutch Cancer Center), Selim Corbacioglu(Unknown), William Hobbs(Vertex Pharmaceuticals (United States)), Markus Y. Mapara(Sheba Medical Center), Laurence Dedeken(Université Libre de Bruxelles), Kevin Boerner(Joslin Diabetes Center)
Cited by 1
Related Papers
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
|New England Journal of Medicine|2018|5.7k
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
|Transplantation and Cellular Therapy|2018|3.6k
<i>LMO2</i> -Associated Clonal T Cell Proliferation in Two Patients after Gene Therapy for SCID-X1
|Science|2003|3.5k
Gene Therapy of Human Severe Combined Immunodeficiency (SCID)-X1 Disease
|Science|2000|2.6k